Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Waldenstrom Macroglobulinemia
Related studies linked through entity extraction aliases.
DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients
- Status
- TERMINATED
- Phase
- PHASE2
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
- Status
- COMPLETED
- Phase
- PHASE1
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
- Status
- WITHDRAWN
- Phase
- PHASE2